IRWD Quote, Financials, Valuation and Earnings

Amgen has a net margin of -90.87% compared to Ironwood Pharmaceuticals's net margin of 21.23%. Ironwood Pharmaceuticals's return on equity of -- beat Amgen's return on equity of 97.08%.

Ironwood Pharmaceuticals has a consensus price target of $0.95, signalling upside risk potential of 33.95%. On the other hand Amgen has an analysts' consensus of $315.35 which suggests that it could grow by 18.62%. Given that Ironwood Pharmaceuticals has higher upside potential than Amgen, analysts believe Ironwood Pharmaceuticals is more attractive than Amgen.

Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.43% to investors and pays a quarterly dividend of $2.38 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Ironwood Pharmaceuticals quarterly revenues are $41.1M, which are smaller than Amgen quarterly revenues of $8.1B. Ironwood Pharmaceuticals's net income of -$37.4M is lower than Amgen's net income of $1.7B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Amgen's PE ratio is 24.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.36x versus 4.22x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Bristol-Myers Squibb has a net margin of -90.87% compared to Ironwood Pharmaceuticals's net margin of 21.93%. Ironwood Pharmaceuticals's return on equity of -- beat Bristol-Myers Squibb's return on equity of 32.01%.

Ironwood Pharmaceuticals has a consensus price target of $0.95, signalling upside risk potential of 33.95%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.20 which suggests that it could grow by 23.15%. Given that Ironwood Pharmaceuticals has higher upside potential than Bristol-Myers Squibb, analysts believe Ironwood Pharmaceuticals is more attractive than Bristol-Myers Squibb.

Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.827%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.25% to investors and pays a quarterly dividend of $0.62 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Ironwood Pharmaceuticals quarterly revenues are $41.1M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Ironwood Pharmaceuticals's net income of -$37.4M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Bristol-Myers Squibb's PE ratio is 17.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.36x versus 1.98x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -90.87% compared to Ironwood Pharmaceuticals's net margin of 21.68%. Ironwood Pharmaceuticals's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Ironwood Pharmaceuticals has a consensus price target of $0.95, signalling upside risk potential of 33.95%. On the other hand Eli Lilly and has an analysts' consensus of $978.82 which suggests that it could grow by 33.25%. Given that Ironwood Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Ironwood Pharmaceuticals is more attractive than Eli Lilly and.

Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ironwood Pharmaceuticals quarterly revenues are $41.1M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Ironwood Pharmaceuticals's net income of -$37.4M is lower than Eli Lilly and's net income of $2.8B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Eli Lilly and's PE ratio is 59.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.36x versus 13.54x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -90.87% compared to Ironwood Pharmaceuticals's net margin of 21.63%. Ironwood Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

Ironwood Pharmaceuticals has a consensus price target of $0.95, signalling upside risk potential of 33.95%. On the other hand Pfizer has an analysts' consensus of $29.25 which suggests that it could grow by 31.27%. Given that Ironwood Pharmaceuticals has higher upside potential than Pfizer, analysts believe Ironwood Pharmaceuticals is more attractive than Pfizer.

Ironwood Pharmaceuticals has a beta of 0.369, which suggesting that the stock is 63.139% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Ironwood Pharmaceuticals quarterly revenues are $41.1M, which are smaller than Pfizer quarterly revenues of $13.7B. Ironwood Pharmaceuticals's net income of -$37.4M is lower than Pfizer's net income of $3B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Pfizer's PE ratio is 16.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.36x versus 2.03x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.